NCT02346240

Brief Summary

The purpose of this study is to investigate the efficacy and safety of two dose levels of certolizumab pegol compared to active comparator and placebo in adults with moderate to severe chronic plaque psoriasis.

Trial Health

93
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
559

participants targeted

Target at P75+ for phase_3

Timeline
Completed

Started Feb 2015

Typical duration for phase_3

Geographic Reach
9 countries

70 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 20, 2015

Completed
6 days until next milestone

First Posted

Study publicly available on registry

January 26, 2015

Completed
16 days until next milestone

Study Start

First participant enrolled

February 11, 2015

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 22, 2016

Completed
2.3 years until next milestone

Results Posted

Study results publicly available

July 18, 2018

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 17, 2018

Completed
Last Updated

July 16, 2021

Status Verified

July 1, 2021

Enrollment Period

1.1 years

First QC Date

January 20, 2015

Results QC Date

June 22, 2018

Last Update Submit

July 15, 2021

Conditions

Keywords

Certolizumab PegolCimziaPsoriasis

Outcome Measures

Primary Outcomes (1)

  • Proportion of Subjects Who Achieve a Psoriasis Activity and Severity Index (PASI75) Response at Week 12

    The PASI75 response assessments are based on at least 75% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.

    Week 12

Secondary Outcomes (6)

  • Proportion of Subjects Who Achieve a Physician's Global Assessment (PGA) Clear or Almost Clear Response (With at Least 2 Category Improvement) at Week 12

    Week 12

  • Proportion of Subjects Who Achieve a Psoriasis Activity and Severity Index (PASI90) Response at Week 12

    Week 12

  • Proportion of Subjects Who Achieve a Psoriasis Activity and Severity Index (PASI75) Response at Week 16

    Week 16

  • Proportion of Subjects Who Achieve a Physician's Global Assessment (PGA) Clear or Almost Clear Response (With at Least 2 Category Improvement) at Week 16

    Week 16

  • Proportion of Subjects Who Achieve a Psoriasis Activity and Severity Index (PASI90) Response at Week 16

    Week 16

  • +1 more secondary outcomes

Study Arms (4)

CZP 200 mg

EXPERIMENTAL

Certolizumab Pegol (CZP) subcutaneous (sc) injection 400 mg at Weeks 0, 2, 4, followed by CZP 200 mg every two weeks (Q2W) from Week 6 to Week 14. The treatment received from Week 16 to Week 48 is based on initial treatment and response to treatment at Week 16: * Subjects with a PASI75 response at Week 16 will be re-randomized to receive either CZP 200 mg Q2W or CZP 400 mg every 4 weeks (Q4W; with Placebo administered on alternate dosing weeks to maintain the blind) or Placebo Q2W. * Subjects who do not achieve a PASI75 response at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study. Subjects can enter a 96-week open-label extension period after completing the Maintenance Period and receive CZP under certain conditions.

Biological: Certolizumab Pegol

CZP 400 mg

EXPERIMENTAL

Certolizumab Pegol subcutaneous (sc) injection 400 mg every two weeks (Q2W) through Week 14. The treatment received from Week 16 to Week 48 is based on initial treatment and response to treatment at Week 16: * Subjects with a PASI75 response at Week 16 will be re-randomized to CZP 200 mg Q2W or CZP 400 mg Q2W or Placebo Q2W. * Subjects who do not achieve a PASI75 response at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study. Subjects can enter a 96-week open-label extension period after completing the Maintenance Period and receive CZP under certain conditions.

Biological: Certolizumab Pegol

Etanercept

ACTIVE COMPARATOR

Etanercept (ETN) subcutaneous (sc) injection 50 mg twice weekly through Week 12. The treatment received from Week 16 to Week 48 is based on initial treatment and response to treatment at Week 16: * Subjects with a PASI75 response at Week 16 will be re-randomized to either Certolizumab Pegol (loading dose of 400 mg at Weeks 16, 18, and 20 followed by 200 mg Q2W) or Placebo Q2W. * Subjects who do not achieve a PASI75 response at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study. Subjects can enter a 96-week open-label extension period after completing the Maintenance Period and receive CZP under certain conditions.

Biological: Etanercept

Placebo

PLACEBO COMPARATOR

Placebo subcutaneous (sc) injection every two weeks (Q2W). The treatment received from Week 16 to Week 48 is based on initial treatment and response to treatment at Week 16: * Subjects with a PASI75 response at Week 16 continue to receive blinded Placebo. * Subjects who do not achieve a PASI75 response at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study. Subjects can enter a 96-week open-label extension period after completing the Maintenance Period and receive CZP under certain conditions.

Other: Placebo

Interventions

* Active Substance: Certolizumab Pegol * Pharmaceutical Form: Solution for injection in pre-filled syringe * Concentration: 200 mg/ mL * Route of Administration: Subcutaneous use

Also known as: Cimzia, CDP870, CZP
CZP 200 mgCZP 400 mg
EtanerceptBIOLOGICAL

* Active Substance: Etanercept * Pharmaceutical Form: Solution for injection in pre-filled syringe * Concentration: 50 mg / mL * Route of Administration: Subcutaneous use

Also known as: Enbrel, ETN
Etanercept
PlaceboOTHER

* Active Substance: Placebo * Pharmaceutical Form: Solution for injection in pre-filled syringe * Concentration: 0.9 % saline * Route of Administration: Subcutaneous use

Also known as: PBO
Placebo

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Provided informed consent
  • Adult men or women \>= 18 years
  • Chronic plaque psoriasis for at least 6 months
  • Baseline psoriasis activity and severity index \>= 12 and body surface area \>= 10 % and Physician's Global Assessments score \>= 3
  • Candidate for systemic psoriasis therapy and/or phototherapy and/or chemophototherapy

You may not qualify if:

  • Erythrodermic, guttate, generalized pustular form of psoriasis
  • History of current, chronic, or recurrent infections of viral, bacterial, or fungal origin as described in the protocol
  • Congestive heart failure
  • History of a lymphoproliferative disorder including lymphoma or current signs and symptoms suggestive of lymphoproliferative disease
  • Concurrent malignancy or a history of malignancy as described in the protocol
  • History of, or suspected, demyelinating disease of the central nervous system (e.g., multiple sclerosis or optic neuritis)
  • Female subjects who are breastfeeding, pregnant, or plan to become pregnant during the study or within 5 months following last dose of study drug in the UK, Czech Republic, Germany, and France, and within 3 months for all other countries. Male subjects who are planning a partner pregnancy during the study or within 5 months following the last dose in France and within 10 weeks in all other countries
  • Any other condition which, in the Investigator's judgment, would make the subject unsuitable for participation in the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (70)

Ps0003 317

Mobile, Alabama, 36608, United States

Location

Ps0003 306

Little Rock, Arkansas, 72204, United States

Location

Ps0003 301

Beverly Hills, California, 90212, United States

Location

Ps0003 307

Los Angeles, California, 90045, United States

Location

Ps0003 405

San Diego, California, 92123, United States

Location

Ps0003 316

Washington D.C., District of Columbia, 20037, United States

Location

Ps0003 304

West Palm Beach, Florida, 33409, United States

Location

Ps0003 302

Springfield, Illinois, 62703, United States

Location

Ps0003 313

West Dundee, Illinois, 60118, United States

Location

Ps0003 310

Indianapolis, Indiana, 46256, United States

Location

Ps0003 400

Henderson, Nevada, 89052, United States

Location

Ps0003 319

Verona, New Jersey, 07044-29, United States

Location

Ps0003 404

Buffalo, New York, 14203, United States

Location

Ps0003 407

Portland, Oregon, 97223, United States

Location

Ps0003 309

Johnston, Rhode Island, 02919, United States

Location

Ps0003 401

Dallas, Texas, 75246, United States

Location

Ps0003 403

Houston, Texas, 77065, United States

Location

Ps0003 406

San Antonio, Texas, 78213, United States

Location

Ps0003 311

Webster, Texas, 77598, United States

Location

Ps0003 345

Dupnitsa, Kyustendil, Bulgaria

Location

Ps0003 343

Sofia, Sofia-Grad, Bulgaria

Location

Ps0003 344

Plovdiv, Bulgaria

Location

Ps0003 342

Varna, Bulgaria

Location

Ps0003 353

Pardubice, District of Columbia, Czechia

Location

Ps0003 351

Pardubice, Czechia

Location

Ps0003 352

Prague, Czechia

Location

Ps0003 350

Ústí nad Labem, Czechia

Location

Ps0003 320

Nice, France

Location

Ps0003 325

Toulouse, France

Location

Ps0003 374

Friedrichshafen, Baden-Wurttemberg, Germany

Location

Ps0003 373

Munich, Bavaria, Germany

Location

Ps0003 368

Frankfurt am Main, Hesse, Germany

Location

Ps0003 378

Bochum, North Rhine-Westphalia, Germany

Location

Ps0003 371

Wuppertal, North Rhine-Westphalia, Germany

Location

Ps0003 370

Mainz, Rhineland-Palatinate, Germany

Location

Ps0003 365

Kiel, Schleswig-Holstein, Germany

Location

Ps0003 363

Erfurt, Thuringia, Germany

Location

Ps0003 367

Berlin, Germany

Location

Ps0003 372

Berlin, Germany

Location

Ps0003 375

Berlin, Germany

Location

Ps0003 369

Dresden, Germany

Location

Ps0003 361

Giessen, Germany

Location

Ps0003 362

Hamburg, Germany

Location

Ps0003 366

Hanover, Germany

Location

Ps0003 381

Orosháza, Bekes County, Hungary

Location

Ps0003 380

Debrecen, Hajdú-Bihar, Hungary

Location

Ps0003 382

Budapest, Hungary

Location

Ps0003 383

Budapest, Hungary

Location

Ps0003 384

Budapest, Hungary

Location

Ps0003 340

Breda, Netherlands

Location

Ps0003 424

Poznan, Greater Poland Voivodeship, Poland

Location

Ps0003 330

Torun, Kuyavian-Pomeranian Voivodeship, Poland

Location

Ps0003 422

Wroclaw, Lower Silesian Voivodeship, Poland

Location

Ps0003 335

Lublin, Lublin Voivodeship, Poland

Location

Ps0003 338

Warsaw, Masovian Voivodeship, Poland

Location

Ps0003 421

Warsaw, Masovian Voivodeship, Poland

Location

Ps0003 333

Bialystok, Podlaskie Voivodeship, Poland

Location

Ps0003 334

Katowice, Silesian Voivodeship, Poland

Location

Ps0003 425

Bialystok, Poland

Location

Ps0003 427

Gdansk, Poland

Location

Ps0003 423

Gdynia, Poland

Location

Ps0003 332

Szczecin, Poland

Location

Ps0003 336

Warsaw, Poland

Location

Ps0003 339

Wroclaw, Poland

Location

Ps0003 390

Dundee, Angus, United Kingdom

Location

Ps0003 391

Hexham, Northumberland, United Kingdom

Location

Ps0003 395

Cardiff, Wales, United Kingdom

Location

Ps0003 393

Edgbaston, United Kingdom

Location

Ps0003 394

Liverpool, United Kingdom

Location

Ps0003 392

Manchester, United Kingdom

Location

Related Publications (3)

  • Lebwohl M, Blauvelt A, Paul C, Sofen H, Weglowska J, Piguet V, Burge D, Rolleri R, Drew J, Peterson L, Augustin M. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). J Am Acad Dermatol. 2018 Aug;79(2):266-276.e5. doi: 10.1016/j.jaad.2018.04.013. Epub 2018 Apr 14.

  • Warren RB, Lebwohl M, Sofen H, Piguet V, Augustin M, Brock F, C Arendt, Fierens F, Blauvelt A. Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial. J Eur Acad Dermatol Venereol. 2021 Dec;35(12):2398-2408. doi: 10.1111/jdv.17486. Epub 2021 Aug 17.

  • Blauvelt A, Paul C, van de Kerkhof P, Warren RB, Gottlieb AB, Langley RG, Brock F, Arendt C, Boehnlein M, Lebwohl M, Reich K. Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies. Br J Dermatol. 2021 Apr;184(4):640-651. doi: 10.1111/bjd.19314. Epub 2020 Sep 6.

Related Links

MeSH Terms

Conditions

Psoriasis

Interventions

Certolizumab PegolEtanercept

Condition Hierarchy (Ancestors)

Skin Diseases, PapulosquamousSkin DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Polyethylene GlycolsPolymersMacromolecular SubstancesImmunoglobulin Fab FragmentsImmunoglobulin FragmentsPeptide FragmentsPeptidesAmino Acids, Peptides, and ProteinsAntibodies, Monoclonal, HumanizedAntibodies, MonoclonalAntibodiesImmunoglobulinsImmunoproteinsBlood ProteinsProteinsSerum GlobulinsGlobulinsImmunoglobulin Fc FragmentsImmunoglobulin Constant RegionsReceptors, Tumor Necrosis FactorReceptors, CytokineReceptors, ImmunologicReceptors, Cell SurfaceMembrane Proteins

Results Point of Contact

Title
UCB
Organization
Cares

Study Officials

  • UCB Cares

    +1 844 599 2273 (UCB)

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
GT60
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR
Expanded Access
Yes

Study Record Dates

First Submitted

January 20, 2015

First Posted

January 26, 2015

Study Start

February 11, 2015

Primary Completion

March 22, 2016

Study Completion

December 17, 2018

Last Updated

July 16, 2021

Results First Posted

July 18, 2018

Record last verified: 2021-07

Locations